Gabriel Abril-Rodriguez and Antoni Ribas
To wait for resistance to drugs to develop in patients and then identify why it happened, will lead to a deadly lag in the design of salvage therapies or indeed preventative treatment approaches.
In our latest manuscript we describe a systematic analysis of negative selection pressures acting on neoantigen forming mutations. Contrary to what is generally believed we did not find any clear evidence of this immunogenic form of selection and the resulting neoantigen depletion.
Turns out there are times when it’s important to improve on mother nature, especially when confronting a life-threatening disease.
Antitumor activity of an engineered decoy receptor targeting CLCF1-CNTFR signaling in lung adenocarcinoma.
In the November issue of Nature Medicine we describe the development of a first-in-class inhibitor of CLCF1 signaling and its effectiveness in several precllinical models of lung adenocarcinoma